Anti-epidermal growth factor receptor strategies for advanced breast cancer.
Department of Breast and Gynecology, Dana Farber Cancer Institute, Harvard University, Boston, Massachusetts, USA.
Susana M
SM
Campos
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000502:physiology; D005260:Female; D018773:Genes, erbB-1; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D008024:Ligands; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology; D020893:Receptor, ErbB-3 / Q000037:antagonists & inhibitors / Q000502:physiology; D066247:Receptor, ErbB-4; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D066246:ErbB Receptors; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; D066247:Receptor, ErbB-4; C512478:EGFR protein, human; C587689:ERBB4 protein, human